See what’s new.
Extellis raises $6.8 M seed round to unlock reliable satellite imagery at an industrial scale
Oversubscribed round, led by Oval Park Capital, funds first orbital demonstration and initial product rollout.
Duke Startup Resolv to Deliver Valuable Building and Construction Insights
Resolv, a spinout of Duke University’s Pratt School of Engineering, closed on $5 million seed funding round to develop metamaterials-based device that could impact the $10 billion building construction and remediation industry.
Duke Inventions Return a Record $115M Revenue in FY25, Highlighting Momentum in Research Translation
OTC reports highest-ever revenue as invention disclosures rise, while Duke Capital Partners delivers its strongest investment year ever.
The Translational Matchmakers: How Technology Marketing Connects Inventors with Industry
At OTC, the Technology Marketing team plays a pivotal role in moving discoveries beyond the lab.
Isolere Bio by Donaldson Passes Most Significant Milestone To-Date, Announces Availability of Manufacturing-Grade IsoTag™ AAV Reagent
Isolere Bio by Donaldson, a Duke spinout, announces the launch of its manufacturing-grade IsoTag™ AAV reagent, marking a major milestone in advancing gene therapy manufacturing technologies.
Gene therapy developed at Duke to be commercialized by a local biotechnology company
A universal gene editing therapy for Pompe disease, invented in the lab of Duke Professor Dwight Koeberl, is licensed for further development by local start-up GeneVentiv.
GeneVentiv Announces Global Licensing Agreement for Universal Gene Editing Therapy for Infantile Onset and Late Onset Pompe Disease
GeneVentiv Therapeutics, a Raleigh-based gene therapy company, has taken an exclusive license to Pompe disease gene editing technology developed in the lab of Professor Dwight Koeberl (Pediatrics, SOM).
Fellow Turned Inventor Gives Glaucoma Care an Upgrade
While Gabriel and Challa iterated on the new and improved GDD, they also tapped into Duke’s innovation ecosystem resources and connected with Duke’s Office for Translation & Commercialization (OTC), Duke’s tech transfer office.
VQ Biomedical secures $5M, including a seed round led by Harbright, WIN, and DCP
VQ Biomedical is a Duke University start-up and DCP portfolio company resulting from the collaboration Duke clinicians and engineers.